Benjamin H. Durham
YOU?
Author Swipe
View article: Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Clonality assessment of known oncogenic mutations in the female GCT cohort.
View article: Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
View article: Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
View article: RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition Open
Histiocytic neoplasms are clonal disorders of the monocyte/macrophage lineage defined by mutations activating mitogen-activated protein kinase (MAPK) signaling. Recently, the MEK1/2 inhibitor cobimetinib was FDA-approved for patients with …
View article: 194 | A NOVEL APPROACH FOR CLASSIFICATION OF SPLENIC B CELL LYMPHOMA USING DNA METHYLATION REVEALS DIVERSE BIOLOGICAL DISEASE MECHANISMS
194 | A NOVEL APPROACH FOR CLASSIFICATION OF SPLENIC B CELL LYMPHOMA USING DNA METHYLATION REVEALS DIVERSE BIOLOGICAL DISEASE MECHANISMS Open
View article: <i>NTRK1</i>-rearranged histiocytosis: clinicopathologic and molecular features
<i>NTRK1</i>-rearranged histiocytosis: clinicopathologic and molecular features Open
Non-Langerhans cell histiocytoses are a diverse group of histiocytic diseases. Different entities are defined based on clinical, histopathologic, and/or molecular characteristics. This study aimed to define NTRK-rearranged histiocytosis. T…
View article: Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation
Inherited resilience to clonal hematopoiesis by modifying stem cell RNA regulation Open
Somatic mutations that increase hematopoietic stem cell (HSC) fitness drive their expansion in clonal hematopoiesis (CH) and predispose to blood cancers. Although CH frequently occurs with aging, it rarely progresses to overt malignancy. P…
View article: The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms Open
View article: Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy Open
Summary Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well as uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (…
View article: Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies
Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies Open
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events i…
View article: Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms
Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms Open
View article: Histiocytic neoplasm subtypes differ in their <i>MAP2K1</i> mutational type
Histiocytic neoplasm subtypes differ in their <i>MAP2K1</i> mutational type Open
[Figure: see text]
View article: Mutant <i>PIK3CA</i> is a targetable driver alteration in histiocytic neoplasms
Mutant <i>PIK3CA</i> is a targetable driver alteration in histiocytic neoplasms Open
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm characterized by the accumulation of clonal mononuclear phagocyte system cells expressing CD1a and CD207. In the past decade, molecular profiling of LCH as well as oth…
View article: Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia Open
BACKGROUND: Hairy cell leukemia (HCL) is characterized by the underlying genetic lesion of BRAFV600E and responsiveness to BRAF inhibitors. We assessed the safety and activity of the BRAF inhibitor vemurafenib combined with obinutuzumab in…
View article: <scp>Genome‐Wide</scp> Association Study Identifies the First Germline Genetic <scp>Variant Associated</scp> With <scp>Erdheim‐Chester</scp> Disease
<span>Genome‐Wide</span> Association Study Identifies the First Germline Genetic <span>Variant Associated</span> With <span>Erdheim‐Chester</span> Disease Open
Objective Erdheim‐Chester disease (ECD) is rare histiocytosis with a wide range of clinical manifestations. Somatic mutations are key to the pathogenesis of the disease; however, the relationship between germline genetic variants and ECD h…
View article: P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS
P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS Open
Topic: 15. Myeloproliferative neoplasms - Biology & Translational Research Background: Myeloproliferative neoplasms (MPNs) are characterized by aberrant activation of the JAK-STAT pathway. Ruxolitinib (RUX), is a JAK1/2 inhibitor used to t…
View article: Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
View article: Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Clonality assessment of known oncogenic mutations in the female GCT cohort.
View article: Data from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Data from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Purpose:To overcome barriers to genomic testing for patients with rare cancers, we initiated a program to offer free clinical tumor genomic testing worldwide to patients with select rare cancer subtypes.Experimental Design:Patients were re…
View article: Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
View article: Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
View article: Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Clonality assessment of known oncogenic mutations in the female GCT cohort.
View article: Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach Open
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
View article: Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms Open
Summary Little is known about outcomes following interruption of targeted therapy in adult patients with histiocytic neoplasms. This is an IRB‐approved study of patients with histiocytic neoplasms whose BRAF and MEK inhibitors were interru…
View article: CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition Open
Histiocytic neoplasms are rare clonal hematopoietic disorders occupying a wide clinical spectrum amongst adults and children.Identification of recurrent somatic mutations in the mitogen activated protein kinase (MAPK) pathway has reframed …
View article: Supplementary Figure from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
Supplementary Figure from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation Open
Supplementary Figure from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
View article: Supplementary Figure from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
Supplementary Figure from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation Open
Supplementary Figure from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
View article: Data from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
Data from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation Open
Recently, screens for mediators of resistance to FLT3 and ABL kinase inhibitors in leukemia resulted in the discovery of LZTR1 as an adapter of a Cullin-3 RING E3 ubiquitin ligase complex responsible for the degradation of RAS GTPases. In …
View article: Data from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
Data from Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation Open
Recently, screens for mediators of resistance to FLT3 and ABL kinase inhibitors in leukemia resulted in the discovery of LZTR1 as an adapter of a Cullin-3 RING E3 ubiquitin ligase complex responsible for the degradation of RAS GTPases. In …
View article: Table S2 from A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1
Table S2 from A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1 Open
Sequence of oligos and plasmids used as well as FACS antibody details